Cord Blood to Be Used in Breast Cancer Study

Publication
Article
OncologyONCOLOGY Vol 13 No 8
Volume 13
Issue 8

The Cord Blood Registry, in collaboration with the Cord Blood Donor Foundation, is participating in a Breast Cancer Study at Stanford University School of Medicine. The study, funded by the Susan G. Komen Breast Cancer Foundation, will

The Cord Blood Registry, in collaboration with the Cord Blood Donor Foundation, is participating in a Breast Cancer Study at Stanford University School of Medicine. The study, funded by the Susan G. Komen Breast Cancer Foundation, will examine the potential links of the prenatal environment to the risk of breast cancer in women. Prenatal Cord Blood Registry clients who know they are expecting baby girls will be offered the opportunity to donate plasma for the study.

The Cord Blood Registry is the nation’s largest family umbilical cord blood bank. Umbilical cord blood stem cells can be easily collected and banked for future use as a type of “biological insurance.” Over 12,000 families have chosen to bank stem cells with the registry.

Seeds of Breast Cancer Planted Very Early?

“We are excited about this opportunity of taking advantage of the unique resources at Cord Blood Registry and Cord Blood Donor Foundation,” said Atsuko Shibata, MD, PhD, assistant professor of health research and policy at Stanford. “The major goal of this study is to compare estrogen levels in cord blood among female babies of the four racial/ethnic groups whose breast cancer risk varies significantly. The study relates to the hypothesis that the formation of breast cancer could start very early in a woman’s life. This is an important research question, and yet difficult to study.”

Dr. Shibata, who is the principal investigator, of the study will be testing samples from baby girls that are of African-American, Asian, Caucasian, and Hispanic descent.

“We look forward to collaborating with the Susan G. Komen Breast Cancer Foundation, Stanford University School of Medicine, and Cord Blood Registry on such an important study. Cord blood is not only an invaluable resource in the treatment of diseases, but equally important in the area of research,” said Gloria J. Ochoa, president, Cord Blood Donor Foundation.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content